Mouse, Rat, Chicken, Cat, Human, Pig, Goldfish
Purified GFAP from pig spinal cord
This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
Monoclonal Anti-Glial Fibrillary Acidic Protein (GFAP) conjugated to Cy3®. The Cy3®-antibody conjugate is extensively dialyzed to remove unbound Cy3®.
Storage instructionsShipped at 4°C. Store at +4°C.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/400. The epitope recognized by the antibody is partially sensitive to prolonged formalin fixation, but is resistant to alcohol-fixation followed by paraffin-embedding and to acetone-fixation of frozen sections.
Use at an assay dependent dilution. PubMed: 20211723
FunctionGFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
Tissue specificityExpressed in cells lacking fibronectin.
Involvement in diseaseDefects in GFAP are a cause of Alexander disease (ALEXD) [MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
Sequence similaritiesBelongs to the intermediate filament family.
Post-translational modificationsPhosphorylated by PKN1.
Cellular localizationCytoplasm. Associated with intermediate filaments.
Immunocytochemistry/ Immunofluorescence - Anti-GFAP antibody [G-A-5] (Cy3 ®) (ab49874)Image from Dotan S et al., Neurotoxicol Teratol. 2010;32(4):481-8. Fig 5.; doi: 10.1016/j.ntt.2010.02.003 with permission from Elsevier.
Immunocytochemistry/Immunofluorescence analysis of chicken astrocytes labelling GFAP (red) with ab49874. Nuclei stained using DAPI (blue). Cells were fixed with methanol for 15 minutes, washed in PBS and permeabilized with PBST for 10 minutes. Cells were then washed and blocked using 1% BSA in PBST for 30 minutes. Cells were incubated with the primary antibody (1:400 in blocking solution) for 1 hour at room temperature or overnight in a humid chamber in 4°C.
References for Anti-GFAP antibody [G-A-5] (Cy3 ®) (ab49874)
This product has been referenced in:
Liu Y et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci33:14231-45 (2013).
Read more (PubMed: 23986257) »
Dotan S et al. An avian model for the reversal of neurobehavioral teratogenicity with neural stem cells. Neurotoxicol Teratol32:481-8 (2010).
Read more (PubMed: 20211723) »